Meta-analysis of the efficacy and safety of nateglinide in Asian type 2 diabetes

蔡晓凌,罗樱樱,韩学尧,纪立农

DOI: https://doi.org/10.3969/j.issn.1006-6187.2013.10.014

2013-01-01

Abstract:Objective To compare the efficacy and safety of nateglinide in Asian T2DM patients. Methods The MEDLINE?,EMBASE?and CENTRAL were searched and qualified studies were included. Results Totally 43qualified studies were included.In terms of HbA1c decline,nateglinide treatment was superior to placebo(WMD:-0.28%,95%CI:-0.41~-0.14)orα-glucosidase inhibitors(AGIs)(WMD:-0.27%,95%CI:-0.53~-0.02),and was comparable with repaglinide or mitiglinide or sulfonylureas(SUs).In terms of fasting glucose lowering,nateglinide treatment was comparable with placebo or AGIs,or SUs or mitiglinide,but was inferior to repaglinide(WMD:0.17mmol/L,95%CI:0.05~0.30).In terms of postprandial glucose lowering,nateglinide treatment was comparable with AGIs or repaglinide,or mitiglinide or SUs.In terms of fasting insulin secretion,nateglinide treatment was comparable with placebo or repaglinide or SUs.In terms of body weight lowering,nateglinide treatment was inferior to AGIs. Conclusion Both the efficacy and safety,as well as the progression of insulin secretion of nateglinide treatment were confirmed in this study.